This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

3 Profitable Pharmaceutical Stocks To Consider As Congress Debates Drug Bill

Click on the interactive chart below to see sales data over time.

Do you expect these stocks to continue to see rising gross margins if Congress passes the Drug Quality and Security Act? Use this list as a starting point for your own analysis.

1. Forest Laboratories Inc. ( FRX): Develops, manufactures, and sells branded and generic forms of ethical drug products.

Market cap at $13.23B, most recent closing price at $50.44.

Gross profit margins increased from 76.03% to 77.26% during the first time interval (12 months ending 2011-03-31 vs. 12 months ending 2010-03-31). For the second time interval, gross margins increased from 77.26% to 77.4% (12 months ending 2012-03-31 vs. 12 months ending 2011-03-31). And for the final time interval, gross margins increased from 77.4% to 78.21% (12 months ending 2013-03-31 vs. 12 months ending 2012-03-31).

Forest Laboratories sells drugs under two segments: Central Nervous System Franchise and Respiratory Franchise.
 

2. Allergan Inc. ( AGN): Operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific.

Market cap at $27.19B, most recent closing price at $94.80.

Gross profit margins increased from 83.33% to 85.32% during the first time interval (12 months ending 2010-12-31 vs. 12 months ending 2009-12-31). For the second time interval, gross margins increased from 85.32% to 86.18% (12 months ending 2011-12-31 vs. 12 months ending 2010-12-31). And for the final time interval, gross margins increased from 86.18% to 86.7% (12 months ending 2012-12-31 vs. 12 months ending 2011-12-31).

Allergan's FDA-approved products include ALPHAGAN, COMBIGAN, and LUNIGAN for glaucoma and other eye conditions as well as BOTOX for overactive bladder, migraines, and several other medical conditions.
 

3. Bristol-Myers Squibb Company ( BMY): Develops, and delivers innovative medicines that help patients prevail over serious diseases.

Market cap at $86.48B, most recent closing price at $51.86.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs